Using a collective impact approach for surveillance of drug overdoses to inform targeted drug-related prevention, treatment, policy-making, and harm reduction strategies is a core focus of work at the AMA.

The AMA is working to advance a public health approach to surveillance that can inform targeted drug-related prevention, treatment, and policy-making, as well as harm reduction strategies.

The AMA urges additional policy changes to accurately track overdose and mortality trends to provide equitable public health interventions that include comprehensive, disaggregated, racial and ethnic data collection related to testing, hospitalization, and mortality associated with opioids and other substances.

Shift from Response to Prevention

Collective Impact of Stakeholders

Each stakeholder plays an important role in the fight to end the drug overdose epidemic, but when stakeholders collaborate, the impact is far greater. This is true for preventative and treatment measures, policies surrounding overdoses, and surveillance efforts.


AMA prescription drug monitoring program national survey

Physicians and other authorized users queried state prescription drug monitoring programs (PDMPs) more than 910,000,000 times in 2020; more than double compared to 2018.

Organized Medicine’s Role in Strengthening a Public Health Approach to Overdose Morbidity and Mortality

AMA President, Susan R. Bailey, MD and the AMA Director of Science and Drug Policy, Amy B. Cadwallader, PhD presented a session at the 2021 Rx Drug Abuse & Heroin Summit that highlighted the reasons why data standardization and public health interventions have been elusive and they provide actionable solutions for states, organizations, and policymakers to meaningfully address the nation’s overdose epidemic.

Reportable and Notifiable Conditions

Be part of the solution.

Join the AMA today and help us lead the effort
to reverse the nation’s opioid epidemic.